Literature DB >> 29734482

Incompletely treated malignancies of the major salivary gland: Toward evidence-based care.

Samantha Tam1, Vlad C Sandulache2, Kareem A Metwalli1, Crosby D Rock3, Salman A Eraj3, Tommy Sheu3, Adel K El-Naggar4, Clifton D Fuller3, Randal S Weber1, Stephen Y Lai1,3.   

Abstract

BACKGROUND: Unexpected malignancy is common in major salivary gland tumors due to variability of workup, creating challenging treatment decisions. The purpose of this study was to define treatment-related outcomes for patients with incompletely treated major salivary gland tumors.
METHODS: A retrospective cohort study was completed of patients with incompletely treated major salivary gland tumors. Tumor burden at presentation was established and treatment categorized. The Cox Proportional Hazards model was used to determine predictors of survival and failure.
RESULTS: Of the 440 included patients, patients with gross residual or metastatic disease had a worse overall survival (OS; P < .001). Presentation status was an independent predictor of OS on multivariate analysis (gross residual disease adjusted hazard ratio [HRadjusted ] 2.55; 95% confidence interval [CI] 1.20-5.30; metastatic disease HRadjusted 9.53; 95% CI 3.04-27.06).
CONCLUSION: Failure to achieve gross total resection during initial surgery resulted in worse OS. Adequate preoperative planning is required for initial surgical management to optimize tumor control and survival.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant chemotherapy; adjuvant radiotherapy; healthcare delivery; reoperation; salivary gland neoplasms

Mesh:

Year:  2018        PMID: 29734482     DOI: 10.1002/hed.25156

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations.

Authors:  Lu Di; Kai Qian; Chengrun Du; Chunying Shen; Ruiping Zhai; Xiayun He; Xiaoshen Wang; Tingting Xu; Chaosu Hu; Hongmei Ying
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.